Sign in or Register   Sign in or Register
  |  

Mouse Anti-CD274 Recombinant Antibody (CBYY-0969) (CBMAB-0972-YY)

This product is mouse antibody that recognizes CD274. The antibody CBYY-0969 can be used for immunoassay techniques such as: WB
See all CD274 antibodies

Summary

Host Animal
Mouse
Specificity
Human
Clone
CBYY-0969
Antibody Isotype
IgG1
Application
WB

Basic Information

Immunogen
Recombinant protein corresponding to human B7-H1
Specificity
Human
Antibody Isotype
IgG1
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Concentration
0.5mg/m
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

Full Name
CD274 Molecule
Entrez Gene ID
29126
UniProt ID
Q9NZQ7
Alternative Names
CD274 Molecule; CD274 Antigen; B7 Homolog 1; Programmed Cell Death 1 Ligand 1; PDCD1 Ligand 1; PDCD1LG1; PDCD1L1;
Function
Plays a critical role in induction and maintenance of immune tolerance to self (PubMed:11015443, PubMed:28813417, PubMed:28813410).
As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed:11015443, PubMed:28813417, PubMed:28813410).
Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed:10581077).
The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed:28813417, PubMed:28813410).
The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (By similarity).
The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (By similarity).
Biological Process
Adaptive immune response Source: UniProtKB-KW
Cell surface receptor signaling pathway Source: UniProtKB
Cellular response to lipopolysaccharide Source: GO_Central
Immune response Source: UniProtKB
Negative regulation of activated T cell proliferation Source: UniProtKB
Negative regulation of CD4-positive, alpha-beta T cell proliferation Source: UniProtKB
Negative regulation of CD8-positive, alpha-beta T cell activation Source: UniProtKB
Negative regulation of interferon-gamma production Source: UniProtKB
Negative regulation of interleukin-10 production Source: UniProtKB
Negative regulation of T cell proliferation Source: GO_Central
Negative regulation of tumor necrosis factor superfamily cytokine production Source: UniProtKB
Positive regulation of activated CD8-positive, alpha-beta T cell apoptotic process Source: UniProtKB
Positive regulation of cell migration Source: Ensembl
Positive regulation of interleukin-10 production Source: UniProtKB
Positive regulation of T cell proliferation Source: GO_Central
Positive regulation of tolerance induction to tumor cell Source: UniProtKB
Response to cytokine Source: AgBase
Signal transduction Source: UniProtKB
T cell costimulation Source: UniProtKB
Toxin transport Source: Ensembl
Cellular Location
Cell membrane; Early endosome membrane; Recycling endosome membrane. Associates with CMTM6 at recycling endosomes, where it is protected from being targeted for lysosomal degradation.
Isoform 1: Cell membrane
Isoform 2: Endomembrane system
Involvement in disease
Truncation of the 3'-untranslated (3'-UTR) region of CD274 transcripts leads to elevated expression of CD274 in multiple cancers including T-cell leukemia, diffuse large B-cell lymphoma and stomach adenocarcinoma (PubMed:27281199). Disruption of 3'-UTR region is caused by structural variants that stabilize CD274 transcripts, leading to overexpression (PubMed:27281199). Increased expression in tumors promotes immune evasion and tumor cell growth by allowing malignant cells to escape destruction by the immune system (PubMed:27281199).
Topology
Extracellular: 19-238
Helical: 239-259
Cytoplasmic: 260-290
PTM
Ubiquitinated; STUB1 likely mediates polyubiquitination of PD-L1/CD274 triggering its degradation.

Verocq, C., Decaestecker, C., Rocq, L., De Clercq, S., Verrellen, A., Mekinda, Z., ... & D'haene, N. (2020). The daily practice reality of PD‑L1 (CD274) evaluation in non‑small cell lung cancer: A retrospective study. Oncology letters, 19(5), 3400-3410.

Riemann, D., Schütte, W., Turzer, S., Seliger, B., & Möller, M. (2020). High PD-L1/CD274 Expression of Monocytes and Blood Dendritic Cells Is a Risk Factor in Lung Cancer Patients Undergoing Treatment with PD1 Inhibitor Therapy. Cancers, 12(10), 2966.

Kim, J. Y., Lee, K. H., Kang, J., Borcoman, E., Saada-Bouzid, E., Kronbichler, A., ... & Gamerith, G. (2019). Hyperprogressive disease during anti-PD-1 (PDCD1)/PD-L1 (CD274) therapy: a systematic review and meta-analysis. Cancers, 11(11), 1699.

Fabrizio, F. P., Trombetta, D., Rossi, A., Sparaneo, A., Castellana, S., & Muscarella, L. A. (2018). Gene code CD274/PD-L1: from molecular basis toward cancer immunotherapy. Therapeutic advances in medical oncology, 10, 1758835918815598.

Huang, C. Y., Chiang, S. F., Ke, T. W., Chen, T. W., You, Y. S., Chen, W. T. L., & Chao, K. C. (2018). Clinical significance of programmed death 1 ligand-1 (CD274/PD-L1) and intra-tumoral CD8+ T-cell infiltration in stage II–III colorectal cancer. Scientific reports, 8(1), 1-10.

Clavé, S., Pijuan, L., Casadevall, D., Taus, Á., Gimeno, J., Hernández‐Llodrà, S., ... & Salido, M. (2018). CD 274 (PDL 1) and JAK 2 genomic amplifications in pulmonary squamous‐cell and adenocarcinoma patients. Histopathology, 72(2), 259-269.

Yang, L., Cai, Y., Zhang, D., Sun, J., Xu, C., Zhao, W., ... & Pan, C. (2018). miR-195/miR-497 regulate CD274 expression of immune regulatory ligands in triple-negative breast cancer. Journal of breast cancer, 21(4), 371-381.

Sun, J., Lian, M., Ma, H., Wang, R., Ma, Z., Wang, H., ... & Fang, J. (2018). Competing endogenous RNA network analysis of CD274, IL‑10 and FOXP3 co‑expression in laryngeal squamous cell carcinoma. Molecular medicine reports, 17(3), 3859-3869.

Lee, S. J., Jun, S. Y., Lee, I. H., Kang, B. W., Park, S. Y., Kim, H. J., ... & Kim, J. G. (2018). CD274, LAG3, and IDO1 expressions in tumor-infiltrating immune cells as prognostic biomarker for patients with MSI-high colon cancer. Journal of cancer research and clinical oncology, 144(6), 1005-1014.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-CD274 Recombinant Antibody (CBYY-0969)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare